You are now leaving Amgen Australia’s website. Amgen Australia takes no responsibility for the information contained on the Amgen international server or site which you will be accessing. The information you are about to access may not comply with the Australian regulatory environment.
For Australian specific enquiries, please click here.
You are now leaving Amgen Australia’s website. Amgen Australia takes no responsibility for, and exercises no control over the organisation, views, or information contained on the server or site which you will be accessing. The information contained might not comply with the Australian regulatory environment.
As a leading biotechnology company, Amgen has harnessed the power of science for over 40 years to advance solutions for some of the world’s most serious illnesses. Against the backdrop of this rich heritage, we have invested in a portfolio of biosimilar medicines that offer the potential to increase patient access to vital treatments. Amgen is well-positioned to create high-quality biosimilars and reliably supply them to patients worldwide.
Amgen is committed to developing high-quality biosimilar medicines for patients. Amgen was one of the first large-scale biotechnology manufacturers, and we have developed some of the most widely used, quality biologic medicines used in the treatment of millions of patients around the world.
In addition to providing the same safety and effectiveness as their reference medicines, biosimilars have the potential to lower healthcare costs by offering different treatment options.1
At Amgen, we are focused on a common goal: to make sure high-quality medicines get to every Amgen patient, every time. With over 40 years of experience in developing innovative biologic therapies, Amgen also has one of the world's largest biosimilars portfolios, providing effective and safe biologic treatments for patients and healthcare systems around the world.
Our story holds over 40 years of experience in developing innovative biologic therapies, which are made from living cells enhancing our development of biosimilars in different therapeutic areas around the world, such as inflammation and oncology.
Biosimilars are biologic medicines designed to work just like another FDA approved medicine, known as the reference product, and are tested to ensure they are safe, effective and highly similar to the reference product.
Since the first biosimilar was approved in Europe in 2006,
Amgen has developed one of the world’s largest biosimilars portfolios Providing effective and safe treatments for patients and healthcare systems .
More than 750,000 people in more than 65 countries have been prescribed Amgen’s biosimilars to date.
Developing a biosimilar is an incredibly complex process. Biosimilars, like all biologics, are produced through an intricate, multistep process, using living cells. The technology we're using to develop and manufacture biologics today is more precise, more accurate, and more quantitative than in years past – giving us the ability to look at multiple attributes to bring reliable, high-quality medicines to patients.3-7
At Amgen, we excel at the highly specialised, iterative process of developing monoclonal antibodies in vitro, scaling up the optimal cell line, time and again, in large-scale bioreactors, and checking and rechecking for batch-to-batch consistency.4,8
At Amgen, we make medicines for serious illnesses and chronic conditions that deeply affect patients’ lives. We know it is imperative patients receive an uninterrupted supply of medicine and that gaps in supply can have serious consequences.
Manufacturers of biologic medicines are responsible for monitoring all steps during product development and manufacturing to ensure that the medicine is pure, has the desired strength and is stable.4 A reliable supply chain is key to this responsibility. Biosimilar supply chains should: